It is natural and customary that at a convenient community pharmacy they expect to receive a prescribed biotherapeutic agent
It's the brand's first skincare product with biotherapeutic agent
Via the transaction, Enterologics acquires BioBalancea[euro](tm)s proprietary biotherapeutic agent
, Probactrix, as well as the firma[euro](tm)s portfolio of intellectual property and regulatory filings.
This work represents the first report of a bioengineered version of CD19-L, a recombinant human biotherapeutic agent
, targeting CD19-positive leukemic stem cells.
The company is also developing a second product, CTV-05, a proprietary biotherapeutic agent
with a potentially broad range of applications in the treatment of gynecological and reproductive infections.
This grant will provide funding for further development of a novel bioengineered derivative of CD19-L, a recombinant human biotherapeutic agent
targeting CD19-positive leukemic stem cells.
Polaris' lead project is ADI-PEG 20, a biotherapeutic agent
that is in advanced clinical development for the treatment of hepatocellular carcinoma and metastatic melanoma.
Huertas positioned and developed the program that was the focus of the company's $185 million acquisition by Genzyme Corporation, which gained FDA approval in 2006 for the first Pompe biotherapeutic agent
announced that the results of a clinical study using PROBACTRIX(TM), BioBalance's novel biotherapeutic agent
, will be presented tomorrow at the 2004 Digestive Disease Week (DDW) in New Orleans.
According to Dennis O'Donnell, President of The BioBalance Corporation, "The milestones for 2004, some of which were achieved during the first quarter, are being announced in order to help shareholders track BioBalance's progress with PROBACTRIX(TM), our lead biotherapeutic agent
for various gastrointestinal (GI) disorders.
Working with management, the new board intends to utilize their experience and contacts in the pharmaceutical industry as part of BioBalance's efforts to accelerate the development and licensing of its lead biotherapeutic agent
, PROBACTRIX(TM) for various gastrointestinal disorders.
a wholly owned subsidiary of New York Health Care (NASDAQ:BBAL), announced today that it has begun enrolling patients in a randomized, double-blind, placebo-controlled trial of its proprietary biotherapeutic agent
, PROBACTRIX(TM), in the dietary management of patients with Irritable Bowel Syndrome (IBS).